Literature DB >> 29162499

Metabolic strategies for the degradation of the neuromodulator agmatine in mammals.

José Benítez1, David García1, Nicol Romero1, Arlette González1, José Martínez-Oyanedel1, Maximiliano Figueroa1, Mónica Salas2, Vasthi López3, María García-Robles4, Peter R Dodd5, Gerhard Schenk5, Nelson Carvajal1, Elena Uribe6.   

Abstract

Agmatine (1-amino-4-guanidinobutane), a precursor for polyamine biosynthesis, has been identified as an important neuromodulator with anticonvulsant, antineurotoxic and antidepressant actions in the brain. In this context it has emerged as an important mediator of addiction/satiety pathways associated with alcohol misuse. Consequently, the regulation of the activity of key enzymes in agmatine metabolism is an attractive strategy to combat alcoholism and related addiction disorders. Agmatine results from the decarboxylation of L-arginine in a reaction catalyzed by arginine decarboxylase (ADC), and can be converted to either guanidine butyraldehyde by diamine oxidase (DAO) or putrescine and urea by the enzyme agmatinase (AGM) or the more recently identified AGM-like protein (ALP). In rat brain, agmatine, AGM and ALP are predominantly localised in areas associated with roles in appetitive and craving (drug-reinstatement) behaviors. Thus, inhibitors of AGM or ALP are promising agents for the treatment of addictions. In this review, the properties of DAO, AGM and ALP are discussed with a view to their role in the agmatine metabolism in mammals.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Agmatinase; Agmatine; Mammals

Mesh:

Substances:

Year:  2017        PMID: 29162499     DOI: 10.1016/j.metabol.2017.11.005

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Transcriptomics combined with metabolomics analysis of the mechanism of agmatine in the treatment of septic liver injury.

Authors:  Ling Huang; Lianfang Gan; Junhua Pan; Lifan Zhong; Qianru Wang; Shanjun Luo; Jia Tian; Huaping Liang
Journal:  Ann Transl Med       Date:  2022-05

2.  Protective Effects of Agmatine Against Corticosterone-Induced Impairment on Hippocampal mTOR Signaling and Cell Death.

Authors:  Gislaine Olescowicz; Tuane B Sampaio; Cristine de Paula Nascimento-Castro; Patricia S Brocardo; Joana Gil-Mohapel; Ana Lúcia S Rodrigues
Journal:  Neurotox Res       Date:  2020-05-12       Impact factor: 3.911

3.  Insights into the Mn2+ Binding Site in the Agmatinase-Like Protein (ALP): A Critical Enzyme for the Regulation of Agmatine Levels in Mammals.

Authors:  María-Belen Reyes; José Martínez-Oyanedel; Camila Navarrete; Erika Mardones; Ignacio Martínez; Mónica Salas; Vasthi López; María García-Robles; Estefania Tarifeño-Saldivia; Maximiliano Figueroa; David García; Elena Uribe
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

4.  Structure of the E. coli agmatinase, SPEB.

Authors:  Iva Chitrakar; Syed Fardin Ahmed; Andrew T Torelli; Jarrod B French
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

5.  Effects of imidazoline agents in a rat conditioned place preference model of addiction.

Authors:  V Şorodoc; G Rusu-Zota; P Nechita; C Moraru; O M Manole
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-08       Impact factor: 3.000

6.  New Insights into the Determinants of Specificity in Human Type I Arginase: Generation of a Mutant That Is Only Active with Agmatine as Substrate.

Authors:  María-Soledad Orellana; Gonzalo A Jaña; Maximiliano Figueroa; José Martínez-Oyanedel; Fabiola E Medina; Estefanía Tarifeño-Saldivia; Marcell Gatica; María Ángeles García-Robles; Nelson Carvajal; Elena Uribe
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.